UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

           February 23, 2006           
(Date of earliest event reported)

LABORATORY CORPORATION OF
AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)
         
DELAWARE   1-11353   13-3757370
  		 
 		  
 
(State or other jurisdiction
of Incorporation) 		  (Commission
File Number)		   (I.R.S. Employer
Identification No.)
         
358 SOUTH MAIN STREET,
BURLINGTON, NORTH CAROLINA 		  27215   336-229-1127
  		 
 		  
 
(Address of principal executive offices)   (Zip Code)
   (Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Information in Report
ITEM 1.01. Entry into a Material Definitive Agreement

On February 23, 2006, the Board of Directors of Laboratory Corporation of America Holdings (the “Company”), after discussion and input from outside compensation consultants, accepted and ratified the conclusions and recommendations of the Company’s Compensation Committee (“Committee”) with respect to the following actions:

2005 Management Incentive Bonus. The Committee authorized the payment of the annual incentive awards with respect to the year ended December 31, 2005. These awards were made pursuant to the Company’s Management Incentive Bonus Plan, as amended and restated (the “MIB Plan”). As in prior years, the Committee used the following factors for the 2005 MIB Plan: Corporate EBITDA, expense control, revenue growth, DSO goal (days), and EPS. A customer retention percentage and goal was established for the 2005 MIB Plan year. The table below sets forth the cash payments to the following executive officers with respect to their earned bonus for 2005.

NAME TITLE MIB PAYMENT
Thomas P. Mac Mahon   Chairman and Chief Executive Officer   $1,322,113  
         
Richard L. Novak   Executive Vice President, Strategic Planning and
Corporate Development 		  542,315
         
Bradford T. Smith   Executive Vice President, Chief Legal Officer and
Secretary 		  444,059
         
Myla P. Lai-Goldman   Executive Vice President, Chief Scientific Officer and
Medical Doctor 		  302,706
         
David P. King   Executive Vice President and Chief Operating Officer   216,697

2006 Base Salaries. The 2006 base salary levels were effective January 1, 2006, for David P. King and William B. Hayes, and are effective March 1, 2006, for the other executive officers listed in the table below.

NAME TITLE 2005 BASE 2006 BASE
Thomas P. Mac Mahon   Chairman and Chief Executive Officer   $                937,125   $            1,000,000  
         
David P. King   Executive Vice President and Chief Operating Officer   341,000   450,000
         
William B. Hayes   Executive Vice President, Chief Financial Officer and Treasurer   250,000   350,000
         
Benjamin R. Miller   Executive Vice President, Oncology Products and Services   250,000   275,000

2006 Management Incentive Bonus. In connection with the Company’s MIB Plan, the Committee used the following factors to set the guidelines for the 2006 MIB Plan: Corporate EBITDA, expense control, revenue growth, bad debt percentage, and EPS. The table below sets forth the 2006 bonus potential for the following executive officers for 2006.

NAME TITLE 2006 BONUS TARGET
Thomas P. Mac Mahon   Chairman and Chief Executive Officer   $ 1,500,000  
         
Richard L. Novak   Executive Vice President, Strategic Planning and
Corporate Development 		  660,000
         
Bradford T. Smith   Executive Vice President, Chief Legal Officer and
Secretary 		  456,435
         
Myla P. Lai-Goldman   Executive Vice President, Chief Scientific Officer and
Medical Doctor 		  279,869
         
David P. King   Executive Vice President and Chief Operating Officer   562,500

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
  Laboratory Corporation of America Holdings
(Registrant)
 		  
Date: March 1, 2006  By:   /s/Bradford T. Smith    
    Bradford T. Smith, Executive Vice President
and Secretary